Multiple Sclerosis news
The Montreal Neurological Institute and Hospital (The Neuro) is home to Canada’s first multiple sclerosis (MS) clinic, and MS research and treatment has been a major focus at The Neuro for many years. The MS clinic employs a highly specialized staff who have access to the latest research data and methods of treatment. It is a clinic where innovation and progress are paramount.
Drug shown to reduce new attacks/symptom progression in some patients In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
A project led by an MNI researcher has been awarded $6.1 million to study progressive multiple sclerosis. The International Progressive MS Alliance has awarded three $6.1 million Collaborative Network Award grants for a total investment of $18.4 million toward accelerating the pace of progressive MS research. More than 2.3 million people worldwide live with MS and more than one million of those living with the disease have progressive MS.
McGill Newsroom 3D depth-sensing camera shown to measure walking difficulties A commonly used device found in living rooms around the world could be a cheap and effective means of evaluating the walking difficulties of multiple sclerosis (MS) patients. The Microsoft Kinect is a 3D depth-sensing camera used in interactive video activities such as tennis and dancing. It can be hooked up to an Xbox gaming console or a Windows computer.
3D depth-sensing camera shown to measure walking difficulties A commonly used device found in living rooms around the world could be a cheap and effective means of evaluating the walking difficulties of multiple sclerosis (MS) patients. The Microsoft Kinect is a 3D depth-sensing camera used in interactive video activities such as tennis and dancing. It can be hooked up to an Xbox gaming console or a Windows computer.
May 2016 - Multiple Sclerosis Awareness Month Multiple sclerosis treatment and research has long been a focus at the Montreal Neurological Institute and Hospital, known simply as The Neuro, an illustrious member of McGill University and the McGill University Health Centre. Indeed, The Neuro introduced Canada’s first MS clinic. The clinic’s highly specialized staff employs the latest research data and treatment methods in a clinical atmosphere of innovation and progress.
A new study led by researchers at the Montreal Neurological Institute and Hospital of McGill University and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis and makes headway in the search for better treatments.
Low levels of vitamin D significantly increase the risk of developing multiple sclerosis (MS), according to a study led by Dr. Brent Richards of the Lady Davis Institute at the Jewish General Hospital, and published in PLOS Medicine. This finding, the result of a sophisticated Mendelian randomization analysis, confirms a long-standing hypothesis that low vitamin D is strongly associated with an increased susceptibility to MS. This connection is independent of other factors associated with low vitamin D levels, such as obesity.
The Montreal Neurological Institute and Hospital – The Neuro at McGill University and the MUHC has Canada’s oldest MS clinic but is always innovating - striving for progress and better treatments for patients. What’s new in MS at The Neuro
The brain is a privileged organ in the body. So vital to life, the brain is protected from alterations elsewhere in the body by a highly regulated gateway known as the blood-brain barrier, which allows only selected molecules to pass through.
What’s new at The Neuro Research: B cell study may lead to treatment options for MS
MS Society of Canada and MS Scientific Research Foundation announce $3.6 million grant to understanding B cells for future MS therapies The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation announced a $3.6 million grant to investigate the role of the B cell, a type of white blood cell of the immune system, in contributing to the development and propagation of multiple sclerosis.
Powerful treatment improves patients’ lives and provides new insight into mechanisms of the disease A new study by Multiple Sclerosis researchers at three leading Canadian centres addresses why bone marrow transplantation (BMT) has positive results in patients with particularly aggressive forms of MS. The transplantation treatment, which is performed as part of a clinical trial and carries potentially serious risks, virtually stops all new relapsing activity as observed upon clinical examination and brain MRI scans. The study reveals how th
A team of basic and clinical scientists led by the University of Montreal Hospital* Research Centre’s (CRCHUM) Dr. Nathalie Arbour has opened the door to significantly improved treatments for the symptoms of Multiple Sclerosis (MS).